Semax Storage and Stability: What Studies Report

Questions about whether Semax needs refrigeration, and how long a reconstituted solution retains its chemical identity, are among the most common search queries about this peptide. This page separates two very different things: what stability science generally says about short peptides, and what the published Semax literature actually measured. The second category is narrower than most readers expect. This page is for educational purposes only and is not medical advice; consult a licensed physician for questions about any substance, product or health condition.

The short answer: the Semax literature is pharmacology, not stability testing

The peer-reviewed Semax papers reviewed for this page are behavioural, histological, biochemical and gene-expression studies. Researchers used them to ask whether the peptide changed outcomes in animal models of cerebral ischaemia, parkinsonism, heavy-metal exposure, stress and Alzheimer's-type pathology. For example, one study reported that Semax and its C-terminal fragment Pro-Gly-Pro activated transcription of neurotrophins and their receptor genes after experimental cerebral ischaemia, and a transcriptome-level analysis described changes in gene expression following cerebral ischaemia–reperfusion in rats. None of these publications was designed as a stability-indicating assay, and none of the abstracts reported shelf-life, degradation kinetics, freeze–thaw testing or container-closure data.

That absence matters. When a literature set contains no stability study, the honest description is "not established in the reviewed literature," not an extrapolation dressed up as a finding. Everything below that is not tied to a citation is general peptide-handling chemistry that applies to the class of short synthetic peptides, and it is presented as background rather than as a Semax-specific measurement.

What Semax is, chemically, and why that shapes stability questions

Semax is a heptapeptide built from the ACTH(4–7) fragment with a C-terminal Pro-Gly-Pro extension. Two structural features are relevant to any stability discussion:

• It is short and unstructured. Seven-residue peptides have no stabilising tertiary fold, so they depend on the surrounding matrix — dry powder versus aqueous buffer — for chemical persistence.
• It contains residues that interact with metals. One 2025 study characterised Semax as a copper chelator and reported that it decreased Cu(II)-catalysed reactive oxygen species production and the cytotoxicity of amyloid-β through metal ion stripping and redox silencing. The researchers framed this as a mechanism relevant to amyloid pathology, not as a shelf-life experiment, but the underlying chemistry — measurable binding of Cu(II) — is the same chemistry that formulation scientists consider when they think about trace metal contamination in solutions.

The methionine and tryptophan-type residues in ACTH fragments are also the residues most often discussed in oxidation studies of peptides generally. Again, oxidation of Semax under defined storage conditions was not quantified in any of the papers cited here.

Lyophilized powder versus reconstituted solution: the general principle

In peptide chemistry, the lyophilized (freeze-dried) state and the dissolved state are treated as two different stability problems.

Lyophilized form

Freeze-drying removes the water that most degradation reactions require. Hydrolysis of peptide bonds, deamidation of asparagine and glutamine, and base-catalysed racemisation all depend on water activity. In a dry, sealed vial held cold and dark, mobility is low and reaction rates are correspondingly slow. This is why research-grade peptides are typically supplied as lyophilized powder rather than as ready-made solutions, and why laboratory documentation for peptides usually distinguishes long-term storage of powder from short-term storage of working solutions.

Reconstituted form

Once a peptide is dissolved, water becomes both solvent and reactant. The usual considerations in the peptide literature are:

• Hydrolysis and fragmentation at labile bonds, accelerated by temperature and by pH extremes.
• Oxidation of susceptible side chains, accelerated by dissolved oxygen, light and trace transition metals.
• Aggregation or adsorption, which can remove peptide from solution without changing the intact molecule's structure.
• Microbial growth in any aqueous solution without a preservative, which is a contamination issue distinct from chemical degradation.

Because these processes are formulation-specific — concentration, buffer, pH, excipients and headspace all matter — a generic "reconstituted peptides last X days" figure cannot be derived from the Semax literature. No study in the verified set measured a solution shelf life for this peptide.

Temperature: what can and cannot be said

Temperature is the single most studied variable in peptide degradation generally, because most degradation pathways follow Arrhenius-type behaviour: rates rise as temperature rises. Laboratories therefore routinely hold lyophilized peptides frozen and working solutions refrigerated, and accelerated-stability programmes deliberately use elevated temperatures to predict long-term behaviour.

None of that constitutes a Semax-specific finding. The question "does Semax need to be refrigerated" has no answer in the reviewed literature, because no cited study reported a comparison of the peptide's integrity at different storage temperatures. What the studies did report were biological effects after administration in animals — for instance, researchers described neuroprotective and antiamnesic effects during experimental ischaemic infarction of the cerebral cortex in rats, and a separate report found that the ACTH(4–10) analogue activated dopaminergic and serotoninergic brain systems in rodents. Those experiments say nothing about how the material behaved in a vial over weeks.

Freeze–thaw cycling

Repeated freezing and thawing is a recognised stress in protein and peptide handling. The mechanisms usually discussed are cryoconcentration of solutes at the ice interface, pH shifts in buffers as components crystallise out, and interfacial stress at growing ice fronts, which can promote aggregation in larger biomolecules. Short peptides are generally considered less aggregation-prone than proteins, but freeze–thaw testing is still a standard part of formal stability programmes precisely because behaviour cannot be assumed.

For Semax, the reviewed literature contains no freeze–thaw data. Any statement about how many cycles a solution "tolerates" would be invented rather than reported.

Light exposure

Photodegradation of peptides is driven mainly by aromatic side chains that absorb ultraviolet light and by photosensitised oxygen chemistry. Formal photostability testing exposes samples to defined light doses and compares them with protected controls; amber glass, foil overwraps and opaque secondary packaging are the common mitigations used in laboratory and pharmaceutical settings. Whether Semax specifically degrades under a defined light challenge was not examined in any cited paper.

Container, surface and concentration effects

Two container-related phenomena dominate the peptide literature:

• Adsorption to surfaces. Dilute peptide solutions can lose measurable material to glass and plastic walls, which lowers the effective concentration without producing degradation products. The effect is most pronounced at low concentrations.
• Leachables and trace metals. Ions leached from glass or introduced by water and excipients can catalyse oxidation. This is where the copper-binding property of Semax becomes chemically interesting: researchers reported measurable Cu(II) interaction and redox silencing by the peptide, which indicates the molecule is not inert toward transition metals. The study was an amyloid-chemistry investigation, so it does not tell readers how a stored Semax solution behaves — but it does show that metal interaction is a real feature of the molecule rather than a theoretical one.

Intranasal solutions and the regulatory picture

A frequent search is how a Semax nasal spray is stored. Two regulatory facts are worth stating plainly. First, Semax is not an approved drug in the United States; it has no FDA marketing authorisation, and peptide material sold for laboratory work is labelled research-use-only, which means it is not manufactured, tested or labelled as a medicine. Second, Semax has a long history of use as a registered intranasal product in Russia, where the published pharmacology base originates. Storage conditions for any registered product are defined by that product's own approved labelling and stability dossier, which is manufacturer- and formulation-specific and was not part of the peer-reviewed papers summarised here. For that reason, this page does not reproduce or paraphrase label storage conditions, and it offers no handling instructions of any kind.

It is also worth noting that intranasal administration was the delivery route used in much of the Russian research tradition around this peptide. Studies in the verified set examined outcomes such as behaviour in rats with 6-OHDA-induced parkinsonism and prevention of learning and memory inhibition after heavy-metal exposure. The study designs concerned biological outcomes; formulation shelf life was outside their scope.

Storage-adjacent safety findings: What Studies Report

Readers sometimes ask whether a degraded or mishandled solution could change a peptide's risk profile. The reviewed literature cannot answer that, because degradation products of Semax were not characterised in any cited paper. What the literature does contain are systemic effects observed in animals given the intact peptide, which are relevant context for understanding that this is a biologically active molecule rather than an inert substance:

• One study reported anticoagulant and antiplatelet effects of Semax under conditions of acute and chronic immobilisation stress in animals.
• Another examined organ-level effects and described the morphofunctional state of hepatocytes during chronic emotional and painful stress.
• A further report described effects on brain cell morphology and proliferative activity in a pilot experimental ischaemia study.

These are findings about administered peptide in animal models. They are not adverse-event data from stored or degraded material, and they are not evidence about human use.

How the evidence gap is usually filled — and why that is a problem

In the absence of compound-specific data, online sources often present confident numbers: a set number of weeks refrigerated, a set number of months frozen. Those figures are typically generic peptide heuristics, not measurements of Semax. A formal stability claim requires a stability-indicating analytical method (commonly HPLC with mass-spectrometric confirmation), defined storage conditions, defined acceptance criteria, and time points with replicate sampling. The papers reviewed here — including recent work on Semax and a derivative in an animal model of Alzheimer's disease and a functional connectomic analysis of Selank and Semax effects — did not include that kind of dataset.

Summary table: evidence status by storage variable

What a reader can take from this

The accurate statement is narrow: the published Semax literature reviewed here documents biological activity in animal and cell models and does not document shelf life, temperature sensitivity, freeze–thaw tolerance or photostability for the peptide. General peptide chemistry explains why the lyophilized and dissolved states are treated differently in laboratories, but general chemistry is not a substitute for a compound-specific stability study. Anyone encountering a specific storage figure for this peptide can reasonably ask which stability-indicating assay produced it and under what conditions. This page is educational only and is not medical advice; questions about any substance belong with a licensed physician.

References

• Semax, a Copper Chelator Peptide, Decreases the Cu(II)-Catalyzed ROS Production and Cytotoxicity of aβ by Metal Ion Stripping and Redox Silencing (Bioinorganic Chemistry and Applications, 2025)
• The Potential of the Peptide Drug Semax and Its Derivative for Correcting Pathological Impairments in the Animal Model of Alzheimer's Disease (Acta Naturae, 2025)
• Novel Insights into the Protective Properties of ACTH(4-7)PGP (Semax) Peptide at the Transcriptome Level Following Cerebral Ischaemia-Reperfusion in Rats (Genes, 2020)
• Functional Connectomic Approach to Studying Selank and Semax Effects (Doklady Biological Sciences, 2020)
• Influence of ACTG(4-7)-PGP (Semax) on Morphofunctional State of Hepatocytes in Chronic Emotional and Painful Stress (Bulletin of Experimental Biology and Medicine, 2017)
• Peptides semax and selank affect the behavior of rats with 6-OHDA induced PD-like parkinsonism (Doklady Biological Sciences, 2017)
• Semax prevents learning and memory inhibition by heavy metals (Doklady Biological Sciences, 2016)
• Anticoagulation and antiplatelet effects of semax under conditions of acute and chronic immobilization stress (Bulletin of Experimental Biology and Medicine, 2010)
• Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia (Cellular and Molecular Neurobiology, 2010)
• The effect of Semax and its C-end peptide PGP on the morphology and proliferative activity of rat brain cells during experimental ischemia: a pilot study (Journal of Molecular Neuroscience, 2011)
• Neuroprotective and antiamnesic effects of Semax during experimental ischemic infarction of the cerebral cortex (Bulletin of Experimental Biology and Medicine, 2006)
• Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents (Neurochemical Research, 2005)